Needham & Company LLC Issues Pessimistic Forecast for Axon Enterprise (NASDAQ:AXON) Stock Price

Axon Enterprise (NASDAQ:AXON) had its target price reduced by investment analysts at Needham & Company LLC from $750.00 to $500.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC‘s target price indicates a potential upside of 30.70% from the stock’s previous close.

A number of other research analysts have also weighed in on AXON. Piper Sandler decreased their price objective on Axon Enterprise from $732.00 to $561.00 and set an “overweight” rating on the stock in a report on Tuesday, October 20th. Morgan Stanley upped their target price on shares of Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Raymond James Financial set a $675.00 target price on shares of Axon Enterprise in a research report on Thursday, October 15th. UBS Group raised their price target on shares of Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group lowered their price target on shares of Axon Enterprise from $715.00 to $675.00 and set a “buy” rating on the stock in a research report on Monday, September 21st. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $672.75.

Axon Enterprise Stock Down 9.8%

AXON opened at $382.56 on Friday. Axon Enterprise has a twelve month low of $339.01 and a twelve month high of $665.07. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. The company has a 50-day moving average price of $447.49 and a 200 day moving average price of $476.73. The company has a market cap of $31.08 billion, a PE ratio of 158.74, a price-to-earnings-growth ratio of 8.06 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Friday, November 6th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.89 by ($0.17). The firm had revenue of $908.55 million during the quarter, compared to analyst estimates of $934.33 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%. The company’s quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.17 earnings per share. Sell-side analysts expect that Axon Enterprise will post 2.10 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, insider Isaiah Fields sold 1,017 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $480.45, for a total value of $488,617.65. Following the transaction, the insider owned 56,264 shares of the company’s stock, valued at $27,032,038.80. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey Kunins sold 9,605 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the transaction, the insider directly owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. This trade represents a 8.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 37,397 shares of company stock worth $21,234,034. 4.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds have recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB lifted its stake in Axon Enterprise by 122,993.6% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 461,601 shares of the biotechnology company’s stock worth $195,036,000 after purchasing an additional 461,226 shares in the last quarter. B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Axon Enterprise during the second quarter worth $3,854,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Axon Enterprise during the first quarter worth $15,067,000. Brown Lisle Cummings Inc. boosted its position in shares of Axon Enterprise by 97,231.4% during the second quarter. Brown Lisle Cummings Inc. now owns 34,066 shares of the biotechnology company’s stock worth $19,098,000 after buying an additional 34,031 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Axon Enterprise by 40.7% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 15,083 shares of the biotechnology company’s stock valued at $6,406,000 after buying an additional 4,360 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon reported record Q3 revenue of $909 million, up 28% year over year. Drone-as-First-Responder revenue grew 43%, Platform Solutions revenue rose 106%, and AI annual recurring revenue surpassed $100 million. Net income was $57 million, versus a loss a year earlier, while adjusted EBITDA increased 33%. Read More.
• Neutral Sentiment: Axon committed an additional $1.2 billion to Skydio, bringing its stake to 37%, and became Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move strengthens Axon’s drone strategy, but the large investment also raises questions about capital allocation and the time needed for returns. Read More.
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million missed analyst estimates of $1.89 and roughly $934 million, respectively. Although revenue grew year over year, the miss is a concern for a high-growth, premium-valued stock. Read More.
• Negative Sentiment: The outlook was weaker than expected: Axon forecast Q4 revenue of $990 million–$1 billion versus consensus near $1.1 billion, and FY 2026 revenue of $3.6 billion versus about $3.7 billion. Reports also cite delays in federal drone business as a factor behind investor concerns. Read More.
• Negative Sentiment: Axon faces a class-action lawsuit over its AI-powered license-plate surveillance network, adding legal and reputational risk. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and connected products for public safety organizations. The company’s portfolio includes TASER conducted-energy weapons, body-worn cameras, in-car cameras, and related hardware designed to support law enforcement, corrections, security, and other emergency-response professionals.

Axon also provides cloud-based software for managing digital evidence, records, workflows, real-time operations, investigations, and communications. Its platform is intended to connect hardware, software, and services across the public-safety ecosystem, helping agencies collect, store, analyze, and share operational information.

The company was founded in 1993 as TASER International by Rick Smith and Tom Smith and adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into a broader technology platform.